Mean HbA1c and mortality in diabetic individuals with heart failure: A population cohort study

European Journal of Heart Failure

Volumn 18, Issue 1, 2016, Pages 94-102

  Elder, Douglas H J ^a   Singh, Jagdeep S S ^a   Levin, Daniel ^a   Donnelly, Louise A ^a   Choy, Anna Maria ^a   George, Jacob ^a   Struthers, Allan D ^a   Doney, Alex S F ^a   Lang, Chim C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Diabetes; HbA1c; Heart failure; Metformin; Outcomes

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN A1C; INSULIN SENSITIZING AGENT; METFORMIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

AGE; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; DIABETIC DIET; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; OUTCOME ASSESSMENT; PHYSIOLOGIC MONITORING; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; UNITED KINGDOM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MORTALITY; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; UNITED KINGDOM;

EID: 84954366179     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.455     Document Type: Article

References (50)

1. MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R, Aguilar D, Krum H, McMurray JJ,. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008; 29: 1224-1240.
2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR,. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
3. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N,. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
4. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M,. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
5. Calles-Escandõn J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, Bonds DE, Fonseca VA, Ismail-Beigi F, Banerji MA, Failor A, Hamilton B,. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33: 721-727.
6. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT,. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
7. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F,. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
8. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R,. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-2948.
9. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL,; SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR-TIMI 53 Randomized Trial. Circulation 2014; 130: 1579-1588.
10. Pazin-Filho A, Kottgen A, Bertoni AG, Russell SD, Selvin E, Rosamond WD, Coresh J,. HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 2008; 51: 2197-2204.
11. Eshaghian S, Horwich TB, Fonarow GC,. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J 2006; 151: 91.
12. Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, Pfeffer MA, Yusuf S,. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008; 168: 1699-1704.
13. Goode KM, John J, Rigby AS, Kilpatrick ES, Atkin SL, Bragadeesh T, Clark AL, Cleland JG,. Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart 2009; 95: 917-923.
14. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A,. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 2009; 54: 422-428.
15. Jeffcoate SL,. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 2004; 21: 657-665.
16. Lind M, Odén A, Fahlén M, Eliasson B,. A systematic review of HbA1c variables used in the study of diabetic complications. Diabetes Metab Synd: Clin Res Rev 2008; 2: 282-293.
17. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-983.
18. Lind M, Oden A, Fahlen M, Eliasson B,. The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables. PLoS One 2009; 4: e4412.
19. Lee DS, Donovan L, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV,. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care 2005; 43: 182-188.
20. Quan H, Li B, Saunders D, Parsons G, Nilsson C, Alibhai A, Ghali W, for the II. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res 2008; 43: 1424-1441.
21. Frolova N, Bakal J, McAlister F, Rowe B, Quan H, Kaul P, Ezekowitz J,. Assessing the use of International Classification of Diseases-10th Revision codes from the emergency department for the identification of acute heart failure. JACC Heart Fail 2015; 3: 386-391.
22. Szwejkowski BR, Elder DH, Shearer F, Jack D, Choy AM, Pringle SD, Struthers AD, George J, Lang CC,. Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study. Eur J Heart Fail 2012; 14: 162-167.
23. Suissa S., Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2008; 167: 492-499.
24. Ake F, Carpenter D,. Extending the Use of PROC PHREG in Survival Analysis. SAS Institute, Inc., Cary, NC, USA.
25. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-2167.
26. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B,. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
27. Yoshida Y, Hagura R, Hara Y, Sugasawa G, Akanuma Y,. Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2001; 51: 195-203.
28. Reichard P, Nilsson BY, Rosenqvist U,. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-309.
29. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389.
30. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW,. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
31. Klein R, Klein BEK, Moss SE, Cruickshanks KJ,. The Wisconsin epidemiologic study of diabetic retinopathy: XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes1. Ophthalmology 1998; 105: 1801-1815.
32. Klein R, Klein BE, Moss SE,. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996; 124: 90-96.
33. Ukena C, Dobre D, Mahfoud F, Kindermann I, Lamiral Z, Tala S, Rossignol P, Turgonyi E, Pitt B, Böhm M, Zannad F,. Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS. J Card Fail 2012; 18: 439-445.
34. Frier BM, Schernthaner G, Heller SR,. Hypoglycemia and cardiovascular risks. Diabetes Care 2011; 34 (Suppl 2): S132-S137.
35. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V,. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003; 26: 1485-1489.
36. Robinson RT, Harris ND, Ireland RH, Lee S, Newman C, Heller SR,. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes 2003; 52: 1469-1474.
37. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD,;, VADT Investigators,. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
38. Bugger H, Abel ED,. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014; 57: 660-671.
39. Ma H, Li S-Y, Xu P, Babcock SA, Dolence EK, Brownlee M, Li J, Ren J,. Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med 2009; 13: 1751-1764.
40. Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, Copeland RJ, Despa F, Hart GW, Ripplinger CM, Bers DM,. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature 2013; 502: 372-376.
41. Wong AK, Symon R, AlZadjali MA, Ang DS, Ogston S, Choy A, Petrie JR, Struthers AD, Lang CC,. The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail 2012; 14: 1303-1310.
42. Evans JM, Doney AS, AlZadjali MA, Ogston SA, Petrie JR, Morris AD, Struthers AD, Wong AK, Lang CC,. Effect of metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol 2010; 106: 1006-1010.
43. Mohan M, McSwiggan S, Baig F, Rutherford L, Lang CC,. Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (The MET-REMODEL Study): rationale and design of the MET-REMODEL study. Cardiovasc Ther 2015; 33: 1-8.
44. Selvin E, Bolen S, Yeh H, Wiley C, Wilson L, Marinopoulos S, Fieldman L, Vassy J, Wilson R, Bass EB, Brancati FL,. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070-2080.
45. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F,. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993; 16: 1387-1390.
46. Johnson JA, Majumdar SR, Simpson SH, Toth EL,. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 200; 25: 2244-2248.
47. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-1667.
48. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
49. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM,. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111583-590.
50. Hancock HC, Close H, Fuat A, Murphy JJ, Hungin APS, Mason JM,. Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 14years: a qualitative study and national survey. BMJ Open 2014; 4: e003866.